Legal counsel advised conversion from LLC to C corporation to simplify the planned capital raise.
BiPAD® has completed development of a highly versatile, easy to use and inexpensive hand switch. Our next steps are three-fold:
Manufacture product in low volume for FDA 510K testing.
Complete FDA 510K Certification.
Perform beta testing using the BiPAD in the operating room.
The planned seed round will fund all three of these steps. We believe that there is a high likelihood that we will be acquired once these three steps are completed. However, our team is also prepared to produce the product for commercialization.